Urinary excretion of 6-hydroxy-5-methoxyindole-2-carboxylic acid and 5-S-cysteinyldopa during PUVA treatment.
The urinary excretion of the eumelanin metabolite 6-hydroxy-5-methoxyindole-2-carboxylic acid and the pheomelanin metabolite 5-S-cysteinyldopa was followed during PUVA treatment for 6 weeks. They showed similar excretion patterns, with the highest values within 1-2 wk.
D000328:Adult; D003548:Cysteinyldopa / Q000652:urine*; D004295:Dihydroxyphenylalanine / Q000031:analogs & derivatives*; D005260:Female; D006801:Humans; D007211:Indoles / Q000652:urine*; D007700:Kinetics; D008297:Male; D008875:Middle Aged; D011701:PUVA Therapy / Q000009:adverse effects*; D010778:Photochemotherapy / Q000009:adverse effects*; D011565:Psoriasis / Q000188:drug therapy / Q000652:urine
D007211:Indoles; D003548:Cysteinyldopa; C017408:6-hydroxy-5-methoxy-2-indolylcarboxylic acid; D004295:Dihydroxyphenylalanine